Delivery Order SPE2DB20D2104-SPE2DB23FR17D
Award Date 11/21/22
Potential Completion Date 11/22/22
Potential Value $2.4K
Federal Agency
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA). The $9,477.37 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The award has an ultimate completion date of November 8, 2022 and is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award is for the supply of RESTASIS 0.05% EYE EMULSION 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $1,299.77 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of January 28, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- The federal contract award is for the delivery of RESTASIS 0.05% eye emulsion (30 count) to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider that is a subsidiary of Cencora, Inc. The $4,321.92 firm fixed-price delivery order has a completion date of November 24, 2021. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant $999,999,999...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA). The $2,559.66 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on January 25, 2024, with a completion date of January 26, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., also known as Amerisourcebergen. The contract is part of a larger $999,999,999.00 Indefinite Delivery Contract...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion products to the Defense Logistics Agency (DLA) Troop Support Medical. The $1,080.48 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on July 21, 2022. The contract has an ultimate completion date of July 22, 2022 and was not set aside for any specific business type. AmerisourceBergen holds a large $999,999,999 Indefinite Delivery Contract (IDC) with the...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The fixed-price delivery order, valued at $4,356.93, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of December 23, 2024 and is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery...
- This federal contract award is to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, to supply RESTASIS 0.05% eye emulsion to the U.S. government. The Delivery Order contract, valued at $4,363.48, was awarded on May 30, 2024 by the Defense Logistics Agency (DLA) Troop Support Medical, with a completion date of May 31, 2024. This contract is not set-aside and is awarded under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA, valued at...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The fixed-price delivery order, valued at $1,298.10, was issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price of $13,514.81 and a period of performance through October 23, 2024. The contract is not associated with a specific set-aside. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA). The $22,402.62 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on September 8, 2021 with a completion date of September 9, 2021. The contract is not set aside for any particular business type. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery...